8-KEarnings & ResultsMaterial AgreementsExhibits & Filings

DEXCOM INC 8-K Report, Material Agreement (Aug 3, 2009)

Filed August 3, 2009For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on August 3, 2009, reporting significant updates regarding its commercialization efforts and financial results. The company entered into material definitive agreements with Animas Corporation to amend existing joint development and commercialization contracts. These amendments focus on the development of a modified DexCom transmitter to support a single, global CGM-enabled insulin pump launch by Animas. The company's second quarter 2009 financial results were also announced. While specific financial figures from the press release are not detailed in this 8-K summary, investors should note that this filing includes the press release containing these results as an exhibit. The amendments with Animas include potential milestone payments for DexCom, contingent on performance qualification and regulatory approvals for the new system outside the United States, indicating progress in strategic partnerships and product development aimed at expanding market reach.

Key Highlights

  • 1DexCom entered into amendments to its Joint Development and Commercialization Agreements with Animas Corporation, effective July 30, 2009.
  • 2The amendments aim to develop a modified DexCom transmitter to support Animas's global CGM-enabled insulin pump launch.
  • 3DexCom is eligible to receive a $1 million milestone payment upon manufacturing line performance qualification for the modified transmitter.
  • 4An additional $4 million milestone payment is possible for DexCom upon the first regulatory body approval outside the United States for the new integrated system.
  • 5The initial term of the OUS Commercialization Agreement is extended to three years from the first commercial product launch, with a backstop date of December 31, 2010.
  • 6The report includes a press release dated August 3, 2009, announcing DexCom's financial results for the quarter ended June 30, 2009.

Frequently Asked Questions

The primary purpose is to collaborate on developing a modified version of DexCom's transmitter that will support Animas's planned launch of a single, global CGM-enabled insulin pump.

DexCom is eligible for two one-time milestone payments: $1 million upon manufacturing line performance qualification for the modified transmitter, and $4 million upon the first regulatory approval outside the United States for the new system.

The initial term of the OUS Commercialization Agreement has been set at three years from the first commercial product launch, with a definitive end date no later than December 31, 2010.

The 8-K filing includes a press release dated August 3, 2009 (Exhibit 99.01) which announces DexCom's financial results for the quarter ended June 30, 2009.